Walleye Capital LLC Ascendis Pharma A/S Transaction History

Walleye Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $51,754 - $70,270	458 Added 82.37%	1,014 $151,000
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $63,803 - $80,984	527 Added 1817.24%	556 $75,000
Q1 2024 May 15, 2024	SELL	$123.45 - $159.4 $139,868 - $180,600	-1,133 Reduced 97.5%	29 $4,000
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $100,048 - $147,992	1,162 New	1,162 $146,000

235

59.5M

80.3K

216K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $9.21B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.